SCHEMBL3894596

SCHEMBL3894596

CN1C(=O)C(=Cc2ccc(-c3ccccc3[N+](=O)[O-])o2)SC1=S

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.65
ALDH1A1 P00352 5/20 0.65
LMNA P02545 4/20 0.65
POLB P06746 3/20 0.65
RAB9A P51151 1/20 0.65
INSR P06213 1/20 0.61
IGF1R P08069 1/20 0.61
GSK3B P49841 2/20 0.59
GSK3A P49840 1/20 0.59
CDK2 P24941 1/20 0.59
HTRA2 O43464 1/20 0.59
HPGD P15428 4/20 0.58
NSD2 O96028 1/20 0.58
MCL1 Q07820 1/20 0.58
BRAF P15056 1/20 0.56
KDM4E B2RXH2 3/20 0.53
KMT2A Q03164 3/20 0.53
PKM P14618 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16491204 1.00 MAPT (0.65) MAPTALDH1A1LMNAPOLBRAB9A
SCHEMBL3894593 1.00 MAPT (0.65) MAPTALDH1A1LMNAPOLBRAB9A
SCHEMBL622937 0.87 CDK2 (0.64) MAPTALDH1A1LMNAPOLBRAB9A
SCHEMBL622938 0.87 CDK2 (0.64) MAPTALDH1A1LMNAPOLBRAB9A
SCHEMBL3135207 0.87 TNFRSF1A (0.68) MAPTALDH1A1INSRIGF1RGSK3B
SCHEMBL3135217 0.87 TNFRSF1A (0.68) MAPTALDH1A1INSRIGF1RGSK3B
SCHEMBL3135211 0.87 TNFRSF1A (0.68) MAPTALDH1A1INSRIGF1RGSK3B
SCHEMBL6279044 0.85 HTRA2 (0.71) MAPTALDH1A1LMNAPOLBRAB9A
SCHEMBL3897914 0.85 HTRA2 (0.71) MAPTALDH1A1LMNAPOLBRAB9A
SCHEMBL3897920 0.85 HTRA2 (0.71) MAPTALDH1A1LMNAPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11135221-B2 Methods for inducing an immune response MOONSHOT PHARMA LLC (US) 2021-10-05 US claimed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 US claimed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 WO claimed
WO-2024255817-A1 SYSTEMS AND METHOD OF INHIBITING NONSENSE-MEDIATED DECAY WITH CIRCULAR RNAS PEKING UNIVERSITY (CN) 2024-12-19 WO disclosed
US-11352624-B2 Reducing nonsense-mediated MRNA decay COLD SPRING HARBOR LABORATORY (US) 2022-06-07 US disclosed
US-20200283762-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2020-09-10 US disclosed
EP-3690048-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2020-08-05 EP disclosed
US-10647983-B2 Reducing nonsense-mediated mRNA decay COLD SPRING HARBOR LABORATORY (US) 2020-05-12 US disclosed
US-20170159049-A9 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2017-06-08 US disclosed
EP-3041958-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2016-07-13 EP disclosed
US-20160194630-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2016-07-07 US disclosed
WO-2015035091-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2015-03-12 WO disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MAPT 1187/4885ALDH1A1 1828/4885LMNA 3753/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 MAPT 880/4885ALDH1A1 3199/4885LMNA 4343/4885
US-11135221-B2 Methods for inducing an immune response UPF1, RNGTT, NSUN2 MAPT 4643/4885ALDH1A1 4810/4885LMNA 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.